PUNE, India, March 17, 2017 /PRNewswire-iReach/ -- The Pulmonary Embolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Pulmonary Embolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=917737
Companies Involved in Therapeutics Development are Accu-Break Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, Dong-A Socio Holdings Co Ltd, F. Hoffmann-La Roche Ltd, Genentech Inc and Verseon Corp.
Drug Profile discussed in this research at DS-1040, Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders, Small Molecules to Inhibit Thrombin for Cardiovascular Diseases, STP-023725, tenecteplase, TMS-007, TRX-1 and warfarin potassium.
Scope of this research: The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Embolism (Cardiovascular). The pipeline guide reviews pipeline therapeutics for Pulmonary Embolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Pulmonary Embolism (Cardiovascular) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Pulmonary Embolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Embolism (Cardiovascular).
Complete research report of 37 pages with 28 List of figures is available at http://www.reportsnreports.com/purchase.aspx?name=917737
Pharmaceutical and Healthcare latest pipeline guide Pulmonary Embolism – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Embolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Media Contact: Ritesh Tiwari, ReportsnReports, + 1 888 391 5441, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com